2023-09-12 06:42:00
French biotechnology company OSE Immunotherapeutics presented positive results of a therapeutic vaccine in patients with advanced lung cancer on Monday. They demonstrate a reduced risk of death compared to chemotherapy.
The French biotechnology company OSE Immunotherapeutics presented on Monday positive results of its therapeutic vaccine Tedopi in patients with advanced lung cancer which demonstrate a reduced risk of death compared to chemotherapy.
“One year after the start of treatment, 44.1% of these patients were still alive in the group receiving the vaccine compared to only 27.5% in the chemotherapy group,” according to the results of a phase 3 clinical trial ( stage which precedes marketing) which were published Monday in the journal Annals of Oncology.
“The study also shows that the vaccine instead of chemotherapy makes it possible to maintain a better quality of life for patients” and “fewer side effects”, indicates Professor Benjamin Besse, director of clinical research at the Institute. Gustave-Roussy and principal investigator of the trial called Atalante-1.
“A new hope”
These results “allow us to envisage new hope for these patients”, declared the general director of Ose Immunotherapeutics, Nicolas Poirier, during an online press conference, emphasizing that more than a thousand injections had were carried out during the various clinical studies.
Therapeutic cancer vaccines aim to educate the immune system to specifically recognize and destroy tumor cells. The Tedopi vaccine is effective in patients with the HLA-A2 gene, present in half of the population, underlines Ose Immunotherapeutics.
Patients entering the randomized trial were previously treated with chemotherapy and immunotherapy.
219 participants
“The study did not complete its recruitment” because of the arrival of Covid-19 and therefore “does not have the desired power” but “it makes it possible to understand which population is real benefit” of the vaccine, namely patients who initially responded to immunotherapy before relapsing, indicated Professor Besse.
A total of 219 patients participated in the study in nine European countries and the United States (139 patients on Tedopi and 80 on chemotherapy). The vaccine was initially administered every three weeks, then every eight weeks for a year, then every 12 weeks.
Top Articles
1694506394
#hope #encouraging #results #therapeutic #vaccine